CVRx to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call on October 29, 2024
CVRx, Inc. (NASDAQ: CVRX), a commercial-stage medical device company specializing in Barostim™, an innovative extravascular implantable neuromodulation device for cardiovascular diseases, has announced its plans to release third quarter 2024 financial and operating results. The results will be released after market close on Tuesday, October 29, 2024, followed by a conference call at 4:30pm Eastern Time to review the results.
Investors and interested parties can access the live webcast of the conference call on the investor relations page of CVRx's website at ir.cvrx.com. For those preferring to listen via telephone, the call-in numbers are 1-877-704-4453 for U.S. callers and 1-201-389-0920 for international callers. It is recommended to dial in approximately ten minutes before the start time.
CVRx, Inc. (NASDAQ: CVRX), un'azienda di dispositivi medici in fase commerciale specializzata in Barostim™, un innovativo dispositivo di neuromodulazione impiantabile extravascolare per le malattie cardiovascolari, ha annunciato i suoi piani per pubblicare i risultati finanziari e operativi del terzo trimestre del 2024. I risultati saranno resi noti dopo la chiusura del mercato martedì, 29 ottobre 2024, seguito da una conferenza telefonica alle 16:30, ora orientale per esaminare i risultati.
Gli investitori e le parti interessate possono accedere alla diretta web della conferenza telefonica nella pagina delle relazioni con gli investitori del sito web di CVRx all'indirizzo ir.cvrx.com. Per coloro che preferiscono ascoltare via telefono, i numeri per chiamare sono 1-877-704-4453 per i chiamanti statunitensi e 1-201-389-0920 per i chiamanti internazionali. Si consiglia di chiamare circa dieci minuti prima dell'orario di inizio.
CVRx, Inc. (NASDAQ: CVRX), una empresa de dispositivos médicos en etapa comercial especializada en Barostim™, un innovador dispositivo de neuromodulación implantable extravascular para enfermedades cardiovasculares, ha anunciado sus planes para publicar sus resultados financieros y operativos del tercer trimestre de 2024. Los resultados se anunciarán después del cierre del mercado el martes 29 de octubre de 2024, seguido de una conferencia telefónica a las 4:30 p.m., hora del Este para revisar los resultados.
Los inversores y partes interesadas pueden acceder a la transmisión en vivo de la conferencia telefónica en la página de relaciones con inversores del sitio web de CVRx en ir.cvrx.com. Para aquellos que prefieran escuchar por teléfono, los números de acceso son 1-877-704-4453 para los llamantes en EE.UU. y 1-201-389-0920 para los llamantes internacionales. Se recomienda marcar aproximadamente diez minutos antes de la hora de inicio.
CVRx, Inc. (NASDAQ: CVRX)는 심혈관 질환을 위한 혁신적인 외곽 이식 가능한 신경 조절 장치인 Barostim™에 전문화된 상업 단계의 의료 기기 회사로, 2024년 3분기 재무 및 운영 결과 발표 계획을 발표했습니다. 결과는 2024년 10월 29일 화요일 시장 마감 후에 발표되며, 결과 검토를 위해 동부 표준시 기준 오후 4:30에 콘퍼런스 콜이 이어집니다.
투자자 및 이해 관계자는 CVRx 웹사이트의 투자자 관계 페이지 ir.cvrx.com에서 콘퍼런스 콜의 실시간 웹캐스트에 접속할 수 있습니다. 전화를 통한 청취를 선호하는 이들을 위해 미국 전화 사용자는 1-877-704-4453, 국제 전화 사용자는 1-201-389-0920을 사용하실 수 있습니다. 시작 시간 약 10분 전에 전화하는 것이 권장됩니다.
CVRx, Inc. (NASDAQ: CVRX), une entreprise de dispositifs médicaux en phase commerciale spécialisée dans Barostim™, un dispositif de neuromodulation implantable extravasculaire innovant pour les maladies cardiovasculaires, a annoncé ses projets de publication des résultats financiers et opérationnels du troisième trimestre 2024. Les résultats seront publiés après la fermeture du marché le mardi 29 octobre 2024, suivis d'une conférence téléphonique à 16h30, heure de l'Est pour examiner les résultats.
Les investisseurs et les parties intéressées peuvent accéder au webinaire en direct de la conférence téléphonique sur la page des relations investisseurs du site Web de CVRx à l'adresse ir.cvrx.com. Pour ceux qui préfèrent écouter par téléphone, les numéros d'appel sont 1-877-704-4453 pour les appelants des États-Unis et 1-201-389-0920 pour les appelants internationaux. Il est recommandé de composer le numéro environ dix minutes avant l'heure de début.
CVRx, Inc. (NASDAQ: CVRX), ein kommerzielles Medizintechnikunternehmen, das sich auf Barostim™, ein innovatives extravasales implantierbares Neuromodulationsgerät für Herz-Kreislauf-Erkrankungen, spezialisiert hat, hat seine Pläne zur Veröffentlichung der finanziellen und betrieblichen Ergebnisse für das dritte Quartal 2024 bekannt gegeben. Die Ergebnisse werden nach Marktschluss am Dienstag, dem 29. Oktober 2024, veröffentlicht, gefolgt von einer Telefonkonferenz um 16:30 Uhr Eastern Time, um die Ergebnisse zu überprüfen.
Investoren und interessierte Parteien können die Live-Webcast der Telefonkonferenz auf der Investor-Relations-Seite der Website von CVRx unter ir.cvrx.com abrufen. Für diejenigen, die lieber telefonisch teilnehmen möchten, sind die Zugangsnummen 1-877-704-4453 für Anrufer in den USA und 1-201-389-0920 für internationale Anrufer. Es wird empfohlen, etwa zehn Minuten vor Beginn der Konferenz anzurufen.
- None.
- None.
MINNEAPOLIS, Oct. 15, 2024 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patients with cardiovascular diseases, today announced that it plans to release third quarter 2024 financial and operating results after market close on Tuesday, October 29, 2024. The Company will host a conference call to review its results at 4:30pm Eastern Time the same day.
A live webcast of the investor conference call will be available online at the investor relations page of the Company’s website at ir.cvrx.com. To listen to the conference call on your telephone, please dial 1-877-704-4453 for U.S. callers, or 1-201-389-0920 for international callers, approximately ten minutes prior to the start time.
About CVRx, Inc.
CVRx is a commercial-stage medical device company focused on the developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim™ is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has also received the CE Mark for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.
Investor Contact:
Mark Klausner or Mike Vallie
ICR Westwicke
443-213-0501
ir@cvrx.com
Media Contact:
Laura O’Neill
Finn Partners
212-867-1762
laura.oneill@finnpartners.com
FAQ
When will CVRx (CVRX) release its Q3 2024 financial results?
What time is the CVRx (CVRX) Q3 2024 earnings conference call?
How can I access the CVRx (CVRX) Q3 2024 earnings call?
What is CVRx's (CVRX) main product?
